CIAM
SYRE icon

Caitong International Asset Management’s Spyre Therapeutics SYRE Stock Holding History

Caitong International Asset Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$178 Sell
2
-284
-99% -$20.7K ﹤0.01% 2030
2026
Q1 		$14.4K Buy
+286
New +$10.8K ﹤0.01% 1040
2025
Q3 		– Sell
-102
Closed -$1.53K – 2496
2025
Q2 		$1.53K Buy
102
+74
+264% +$1.09K ﹤0.01% 1464
2025
Q1 		$452 Buy
28
+14
+100% +$291 ﹤0.01% 1800
2024
Q4 		$326 Buy
+14
New +$411 ﹤0.01% 1526

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Caitong International Asset Management's SYRE Position: Q2 2026 in Review

Caitong International Asset Management reduced its Spyre Therapeutics (SYRE) stake by 99% in Q2 2026, selling an estimated $20.7K and leaving 2 shares worth $178. The position accounts for ﹤0.01% of the portfolio, ranked #2030.

Caitong International Asset Management first reported a position in SYRE in Q4 2024 and has held it in 5 quarters since. The position peaked at $14.4K in Q1 2026. 265 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Caitong International Asset Management held 2 shares of Spyre Therapeutics worth $178 as of Q2 2026.
  • Caitong International Asset Management sold 284 Spyre Therapeutics shares in Q2 2026, an estimated $20.7K.
  • Spyre Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2030 holding.
  • Caitong International Asset Management first reported a position in Spyre Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Caitong International Asset Management's Spyre Therapeutics position peaked at $14.4K in Q1 2026.
  • 265 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.